{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:03:11Z","timestamp":1773871391757,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04806-6","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T07:17:28Z","timestamp":1759735048000},"page":"1335-1348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative digital pathology reveals morphological and molecular correlates of tumor aggressiveness in prostate cancer"],"prefix":"10.1007","volume":"58","author":[{"given":"Francisco","family":"Araujo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Velozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vania","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1bio","family":"T\u00e1vora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"4806_CR1","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/cancers16091686","volume":"16","author":"A Hijazi","year":"2024","unstructured":"Hijazi A, Bifulco C, Baldin P, Galon J (2024) Digital pathology for better clinical practice. Cancers 16:1686. https:\/\/doi.org\/10.3390\/cancers16091686","journal-title":"Cancers"},{"key":"4806_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2024.100383","volume":"15","author":"A Lopes","year":"2024","unstructured":"Lopes A, Ward AD, Cecchini M (2024) Eye tracking in digital pathology: a comprehensive literature review. J Pathol Inform 15:100383. https:\/\/doi.org\/10.1016\/j.jpi.2024.100383","journal-title":"J Pathol Inform"},{"key":"4806_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1189370","author":"M He","year":"2023","unstructured":"He M, Cao Y, Chi C, Yang X, Ramin R, Wang S, Yang G, Mukhtorov O, Zhang L, Kazantsev A, Enikeev M, Hu K (2023) Research progress on deep learning in magnetic resonance imaging-based diagnosis and treatment of prostate cancer: a review on the current status and perspectives. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2023.1189370","journal-title":"Front Oncol"},{"key":"4806_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.urolonc.2024.03.003","volume":"42","author":"D Paralkar","year":"2024","unstructured":"Paralkar D, Akbari A, Aron M (2024) Prostatic adenocarcinoma: molecular underpinnings and treatment-related options. Urol Oncol Semin Orig Investig 42:203\u2013210. https:\/\/doi.org\/10.1016\/j.urolonc.2024.03.003","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"4806_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/geriatrics1040027","volume":"1","author":"V Vaidyanathan","year":"2016","unstructured":"Vaidyanathan V, Karunasinghe N, Jabed A, Pallati R, Kao C, Wang A, Marlow G, Ferguson L (2016) Prostate cancer: is it a battle lost to age? Geriatrics 1:27. https:\/\/doi.org\/10.3390\/geriatrics1040027","journal-title":"Geriatrics"},{"key":"4806_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11912-025-01653-7","volume":"27","author":"C Leit\u00e3o","year":"2025","unstructured":"Leit\u00e3o C, Neto V, Silva L, Estrela M, Fardilha M, Roque F, Herdeiro MT (2025) Perceptions, knowledge, and attitudes of general population about prostate cancer-associated risk factors: a systematic review of qualitative studies focusing on lifestyle. Curr Oncol Rep 27:375\u2013389. https:\/\/doi.org\/10.1007\/s11912-025-01653-7","journal-title":"Curr Oncol Rep"},{"key":"4806_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.urology.2021.05.028","volume":"155","author":"AB Hesterberg","year":"2021","unstructured":"Hesterberg AB, Gordetsky JB, Hurley PJ (2021) Cribriform prostate cancer: clinical pathologic and molecular considerations. Urology 155:47\u201354. https:\/\/doi.org\/10.1016\/j.urology.2021.05.028","journal-title":"Urology"},{"key":"4806_CR8","first-page":"11","volume":"503","author":"JJ Heidelbaugh","year":"2021","unstructured":"Heidelbaugh JJ, Hadj-Moussa M (2021) Men\u2019s health: prostate cancer screening. FP Essent 503:11\u201317","journal-title":"FP Essent"},{"key":"4806_CR9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.suc.2015.05.001","volume":"95","author":"W Tabayoyong","year":"2015","unstructured":"Tabayoyong W, Abouassaly R (2015) Prostate cancer screening and the associated controversy. Surg Clin N Am 95:1023\u20131039. https:\/\/doi.org\/10.1016\/j.suc.2015.05.001","journal-title":"Surg Clin N Am"},{"key":"4806_CR10","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.3390\/jcm9123826","volume":"9","author":"A Patasius","year":"2020","unstructured":"Patasius A, Krilaviciute A, Smailyte G (2020) Prostate cancer screening with PSA: ten years\u2019 experience of population based early prostate cancer detection programme in Lithuania. J Clin Med 9:3826. https:\/\/doi.org\/10.3390\/jcm9123826","journal-title":"J Clin Med"},{"key":"4806_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41698-022-00266-8","volume":"6","author":"RJ Klein","year":"2022","unstructured":"Klein RJ, Vertosick E, Sjoberg D, Ulmert D, R\u00f6nn A-C, H\u00e4ggstr\u00f6m C, Thysell E, Hallmans G, Dahlin A, Stattin P, Melander O, Vickers A, Lilja H (2022) Prostate cancer polygenic risk score and prediction of lethal prostate cancer. NPJ Precis Oncol 6:25. https:\/\/doi.org\/10.1038\/s41698-022-00266-8","journal-title":"NPJ Precis Oncol"},{"key":"4806_CR12","doi-asserted-by":"publisher","first-page":"2028320","DOI":"10.1001\/jamanetworkopen.2020.28320","volume":"3","author":"L Xia","year":"2020","unstructured":"Xia L, Talwar R, Chelluri RR, Guzzo TJ, Lee DJ (2020) Surgical delay and pathological outcomes for clinically localized high-risk prostate cancer. JAMA Netw Open 3:2028320. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.28320","journal-title":"JAMA Netw Open"},{"key":"4806_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.urolonc.2024.06.003","volume":"43","author":"VM Sundaresan","year":"2025","unstructured":"Sundaresan VM, Smani S, Rajwa P, Renzulli J, Sprenkle PC, Kim IY, Leapman MS (2025) Prostate-specific antigen screening for prostate cancer: diagnostic performance, clinical thresholds, and strategies for refinement. Urol Oncol Semin Orig Investig 43:41\u201348. https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.003","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"4806_CR14","first-page":"149","volume":"45","author":"H Saeidi","year":"2023","unstructured":"Saeidi H, Ismail P, Raju CS, Khairul-Asri MG, Bakrin IH (2023) Genetic alterations in prostate cancer as diagnostic and prognostic markers. Malays J Pathol 45:149\u2013155","journal-title":"Malays J Pathol"},{"key":"4806_CR15","doi-asserted-by":"publisher","DOI":"10.22037\/uj.v18i.6828","author":"R Falahatkar","year":"2021","unstructured":"Falahatkar R, Mokhtari G, Momeni-Moghaddam M, Teimoori M, Aal HB, Akhavan A, Falahatkar S, Esmaeili S (2021) An update on biochemical and genomic markers for prostate cancer. Urol J. https:\/\/doi.org\/10.22037\/uj.v18i.6828","journal-title":"Urol J"},{"key":"4806_CR16","doi-asserted-by":"publisher","first-page":"34007","DOI":"10.7759\/cureus.34007","volume":"15","author":"M Vila\u00e7a","year":"2023","unstructured":"Vila\u00e7a M, Pinto JC, Magalh\u00e3es H, Reis F, Mesquita A (2023) Tumor-infiltrating lymphocytes in localized prostate cancer: do they play an important role? Cureus 15:34007. https:\/\/doi.org\/10.7759\/cureus.34007","journal-title":"Cureus"},{"key":"4806_CR17","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1080\/0284186X.2023.2254480","volume":"62","author":"V Spyratou","year":"2023","unstructured":"Spyratou V, Freyhult E, Bergh A, Thellenberg-Karlsson C, Wikstr\u00f6m P, Wel\u00e9n K, Josefsson A (2023) Ki67 and prostate specific antigen are prognostic in metastatic hormone na\u00efve prostate cancer. Acta Oncol 62:1698\u20131706. https:\/\/doi.org\/10.1080\/0284186X.2023.2254480","journal-title":"Acta Oncol"},{"key":"4806_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.euros.2021.05.004","volume":"29","author":"SR Walker","year":"2021","unstructured":"Walker SR, Abdelsalam R, Ghosh S, Livingstone J, Palanisamy N, Boutros PC, Yip SM, Lees-Miller SP, Bismar TA (2021) Decreased ATM protein expression is substantiated with PTEN loss in defining aggressive phenotype of prostate cancer associated with lethal disease. Eur Urol Open Sci 29:93\u2013101. https:\/\/doi.org\/10.1016\/j.euros.2021.05.004","journal-title":"Eur Urol Open Sci"},{"key":"4806_CR19","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.juro.2016.11.079","volume":"197","author":"WS Ham","year":"2017","unstructured":"Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M (2017) The impact of downgrading from biopsy Gleason 7 to prostatectomy Gleason 6 on biochemical recurrence and prostate cancer specific mortality. J Urol 197:1060\u20131067. https:\/\/doi.org\/10.1016\/j.juro.2016.11.079","journal-title":"J Urol"},{"key":"4806_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.euros.2024.09.007","volume":"69","author":"J Karwacki","year":"2024","unstructured":"Karwacki J, Stodolak M, D\u0142ubak A, Nowak Gurwin A, Kowalczyk K, Kie\u0142b P, Holdun N, Szlasa W, Krajewski W, Ha\u0142o\u0144 A, Karwacka A, Szyde\u0142ko T, Ma\u0142kiewicz B (2024) Association of lymphovascular invasion with biochemical recurrence and adverse pathological characteristics of prostate cancer: a systematic review and meta-analysis. Eur Urol Open Sci 69:112\u2013126. https:\/\/doi.org\/10.1016\/j.euros.2024.09.007","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"4806_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/PAS.0000000000000626","volume":"40","author":"KA Iczkowski","year":"2016","unstructured":"Iczkowski KA et al (2016) Cribriform and intraductal prostate cancer are associated with increased risk of disease progression and death. Am J Surg Pathol 40(6):727\u2013733. https:\/\/doi.org\/10.1097\/PAS.0000000000000626","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"4806_CR22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41379-018-0180-3","volume":"32","author":"E Hollemans","year":"2019","unstructured":"Hollemans E et al (2019) Cribriform architecture in prostate cancer: correlation with outcome in a multi-institutional study. Mod Pathol 32(5):690\u2013700. https:\/\/doi.org\/10.1038\/s41379-018-0180-3","journal-title":"Mod Pathol"},{"issue":"8","key":"4806_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"GJLH Van Leenders","year":"2020","unstructured":"Van Leenders GJLH et al (2020) The 2019 International Society of Urological Pathology (JSUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 44(8):87\u201399. https:\/\/doi.org\/10.1097\/PAS.0000000000001497","journal-title":"Am J Surg Pathol"},{"key":"4806_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-1-4939-7845-8_6","volume":"1786","author":"T Vlajnic","year":"2018","unstructured":"Vlajnic T, Eppenberger-Castori S, Bubendorf L. Protocols for tissue microarrays in prostate cancer studies. In: Culig Z, editor. Prostate cancer. Methods in Molecular Biology. Vol. 1786. New York, NY: Humana Press; 2018. p. 157-165. doi:10.1007\/978-1-4939-7845-8_6","journal-title":"Methods Molecular Biology"},{"key":"4806_CR25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12935-020-01273-0","volume":"20","author":"M Ye","year":"2020","unstructured":"Ye M, Huang D, Zhang Q, Weng W, Tan C, Qin G, Jiang W, Sheng W, Wang L (2020) Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections. Cancer Cell Int 20:186. https:\/\/doi.org\/10.1186\/s12935-020-01273-0","journal-title":"Cancer Cell Int"},{"key":"4806_CR26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.71265","author":"KH Stopsack","year":"2021","unstructured":"Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vaselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA (2021) Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. eLife. https:\/\/doi.org\/10.7554\/eLife.71265","journal-title":"eLife"},{"key":"4806_CR27","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, James JA, Salto-Tellez M, Hamilton PW (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5","journal-title":"Sci Rep"},{"key":"4806_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1089\/bio.2020.0105","volume":"19","author":"C Greene","year":"2021","unstructured":"Greene C, O\u2019Doherty E, Sidi FA, Bingham V, Fisher NC, Humphries MP, Craig SG, Harewood L, McQuaid S, Lewis C, James J (2021) The potential of digital image analysis to determine tumor cell content in biobanked formalin-fixed, paraffin-embedded tissue samples. Biopreserv Biobank 19:324\u2013331. https:\/\/doi.org\/10.1089\/bio.2020.0105","journal-title":"Biopreserv Biobank"},{"key":"4806_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.712944","author":"J Moratin","year":"2021","unstructured":"Moratin J, Mock A, Obradovic S, Metzger K, Flechtenmacher C, Zaoui K, Fr\u00f6hling S, J\u00e4ger D, Krauss J, Hoffmann J, Freier K, Horn D, Hess J, Freudlsperger C (2021) Digital pathology scoring of immunohistochemical staining reliably identifies prognostic markers and anatomical associations in a large cohort of oral cancers. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.712944","journal-title":"Front Oncol"},{"key":"4806_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41241-018-0071-y","volume":"39","author":"CG Pican\u00e7o-Albuquerque","year":"2019","unstructured":"Pican\u00e7o-Albuquerque CG, Vidotto T, Pereira CS, Saggioro FP, Jamaspishvili T, Koti M, Berman DM, Squire JA, Reis RB (2019) PTEN loss in Gleason grade 7 prostate tumors exhibits intratumoral heterogeneity and is associated with unfavorable pathological features. Appl Cancer Res 39:1. https:\/\/doi.org\/10.1186\/s41241-018-0071-y","journal-title":"Appl Cancer Res"},{"key":"4806_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-024-03999-y","author":"O Hommerding","year":"2024","unstructured":"Hommerding O, Bernhardt M, Kreft T, Scherping A, Abbas M, Baretton G, Br\u00e4sen JH, Breyer J, Darr C, Dressler FF, Ellinger J, Erber R, Esposito I, Hartmann A, Hartmann W, Heitplatz B, Kreipe H, Lafos M, Linxweiler J, Lopez-Cotarelo C, Sailer V, Reis H, Saar M, Schildhaus H-U, Schlack K, Schmid M, Seidl M, Semjonow A, Sommer U, Stahl PR, Tischler V, Weber F, Wulf A-L, Wullich B, Kristiansen G (2024) High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial. Virchows Arch. https:\/\/doi.org\/10.1007\/s00428-024-03999-y","journal-title":"Virchows Arch"},{"key":"4806_CR32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80997","author":"B Dallang","year":"2025","unstructured":"Dallang B, Ezike KN, Emmanuel I, Mandong BM, Dauda AM, Akpa PO, Oguntebi EE (2025) Prognostic significance of Ki67 expression in prostate cancer in Nigerians: a single-center study. Cureus. https:\/\/doi.org\/10.7759\/cureus.80997","journal-title":"Cureus"},{"key":"4806_CR33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili T, Berman DM, Ross AE, Scher HI, Marzo AMD, Squire JA, Lotan TL (2018) Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 15:222\u2013234. https:\/\/doi.org\/10.1038\/nrurol.2018.9","journal-title":"Nat Rev Urol"},{"key":"4806_CR34","doi-asserted-by":"publisher","first-page":"484","DOI":"10.21037\/tau.2018.03.20","volume":"7","author":"M Sharma","year":"2018","unstructured":"Sharma M, Miyamoto H (2018) Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer. Transl Androl Urol 7:484\u2013489. https:\/\/doi.org\/10.21037\/tau.2018.03.20","journal-title":"Transl Androl Urol"},{"key":"4806_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/his.15012","volume":"83","author":"M Bogaard","year":"2023","unstructured":"Bogaard M, Skotheim RI, Maltau AV, Kidd SG, Lothe RA, Axcrona K, Axcrona U (2023) \u2018High proliferative cribriform prostate cancer\u2019 defines a patient subgroup with an inferior prognosis. Histopathology 83:853\u2013869. https:\/\/doi.org\/10.1111\/his.15012","journal-title":"Histopathology"},{"key":"4806_CR36","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/cancers17071064","volume":"17","author":"W-A Kwon","year":"2025","unstructured":"Kwon W-A, Joung JY (2025) Immunotherapy in prostate cancer: from a \u201ccold\u2019\u2019 tumor to a \u201chot\u2019\u2019 prospect. Cancers 17:1064. https:\/\/doi.org\/10.3390\/cancers17071064","journal-title":"Cancers"},{"issue":"6","key":"4806_CR37","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.ajpath.2018.02.017","volume":"188","author":"MC Haffner","year":"2018","unstructured":"Haffner MC et al (2018) Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer. Am J Pathol 188(6):1478\u20131485. https:\/\/doi.org\/10.1016\/j.ajpath.2018.02.017","journal-title":"Am J Pathol"},{"issue":"10","key":"4806_CR38","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP et al (2019) Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Investig 129(10):4492\u20134505. https:\/\/doi.org\/10.1172\/JCI128212","journal-title":"J Clin Investig"},{"issue":"7","key":"4806_CR39","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700\u2013712. https:\/\/doi.org\/10.1016\/S1470-2045(14)70189-5","journal-title":"Lancet Oncol"},{"issue":"1","key":"4806_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11523-019-00680-1","volume":"15","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES et al (2020) Immunotherapy for prostate cancer: biology and clinical trials. Target Oncol 15(1):63\u201375. https:\/\/doi.org\/10.1007\/s11523-019-00680-1","journal-title":"Target Oncol"},{"key":"4806_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.12.003","author":"L Brea","year":"2025","unstructured":"Brea L, Yu J (2025) Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer. Trends Endocrinol Metab. https:\/\/doi.org\/10.1016\/j.tem.2024.12.003","journal-title":"Trends Endocrinol Metab"},{"key":"4806_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7086","author":"K Shimodaira","year":"2024","unstructured":"Shimodaira K, Inoue R, Hashimoto T, Satake N, Shishido T, Namiki K, Harada K, Nagao T, Ohno Y (2024) Significance of the cribriform morphology area ratio for biochemical recurrence in Gleason score 4+4 prostate cancer patients following robot-assisted radical prostatectomy. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.7086","journal-title":"Cancer Med"},{"key":"4806_CR43","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3390\/cancers15051372","volume":"15","author":"R Osiecki","year":"2023","unstructured":"Osiecki R, Kozikowski M, Sarecka-Hujar B, Pyzlak M, Dobruch J (2023) Prostate cancer morphologies: cribriform pattern and intraductal carcinoma relations to adverse pathological and clinical outcomes\u2014systematic review and meta-analysis. Cancers 15:1372. https:\/\/doi.org\/10.3390\/cancers15051372","journal-title":"Cancers"},{"key":"4806_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.humpath.2021.09.005","volume":"118","author":"Z Chen","year":"2021","unstructured":"Chen Z, Pham H, Abreu A, Amin MB, Sherrod AE, Xiao G-Q, Aron M (2021) Prognostic value of cribriform size, percentage, and intraductal carcinoma in Gleason score 7 prostate cancer with cribriform Gleason pattern 4. Hum Pathol 118:18\u201329. https:\/\/doi.org\/10.1016\/j.humpath.2021.09.005","journal-title":"Hum Pathol"},{"key":"4806_CR45","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41379-022-01009-7","volume":"35","author":"E Chan","year":"2022","unstructured":"Chan E, McKenney JK, Hawley S, Corrigan D, Auman H, Newcomb LF, Boyer HD, Carroll PR, Cooperberg MR, Klein E, Fazli L, Gleave ME, Hurtado-Coll A, Simko JP, Nelson PS, Thompson IM, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Lin DW, Brooks JD, Feng Z, Nguyen JK (2022) Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for \u201clarge\u2019\u2019 cribriform prostatic adenocarcinoma. Mod Pathol 35:1092\u20131100. https:\/\/doi.org\/10.1038\/s41379-022-01009-7","journal-title":"Mod Pathol"},{"key":"4806_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-025-04117-2","author":"LJ Kroon","year":"2025","unstructured":"Kroon LJ, Leeuwenburgh KP, Remmers S, Kweldam CF, Bergh RCN, Bangma CH, Leenders GJLH (2025) Comparison of highest and overall percentage Gleason pattern 4 in prostate cancer biopsies. Virchows Arch. https:\/\/doi.org\/10.1007\/s00428-025-04117-2","journal-title":"Virchows Arch"},{"key":"4806_CR47","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1158\/1078-0432.CCR-20-0764","volume":"26","author":"H Kaur","year":"2020","unstructured":"Kaur H, Salles DC, Murali S, Hicks JL, Nguyen M, Pritchard CC, Marzo AMD, Lanchbury JS, Trock BJ, Isaacs WB, Timms KM, Antonarakis ES, Lotan TL (2020) Genomic and clinicopathologic characterization of ATM-deficient prostate cancer. Clin Cancer Res 26:4869\u20134881. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0764","journal-title":"Clin Cancer Res"},{"key":"4806_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33780-1","author":"HY Wong","year":"2022","unstructured":"Wong HY, Sheng Q, Hesterberg AB, Croessmann S, Rios BL, Giri K, Jackson J, Miranda AX, Watkins E, Schaffer KR, Donahue M, Winkler E, Penson DF, Smith JA, Herrell SD, Luckenbaugh AN, Barocas DA, Kim YJ, Graves D, Giannico GA, Rathmell JC, Park BH, Gordetsky JB, Hurley PJ (2022) Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-022-33780-1","journal-title":"Nat Commun"},{"issue":"5","key":"4806_CR49","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/PAS.0000000000000595","volume":"40","author":"K Arora","year":"2016","unstructured":"Arora K et al (2016) Interobserver reproducibility and prognostic value of percentage Gleason pattern 4 in prostate needle biopsies. Am J Surg Pathol 40(5):667\u2013672. https:\/\/doi.org\/10.1097\/PAS.0000000000000595","journal-title":"Am J Surg Pathol"},{"issue":"14","key":"4806_CR50","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-19-3676","volume":"26","author":"HB Kaur","year":"2020","unstructured":"Kaur HB et al (2020) Loss of ATM protein expression is associated with worse outcomes in prostate cancer and is detectable in biopsy specimens. Clin Cancer Res 26(14):3347\u20133358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3676","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4806_CR51","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41379-021-00752-7","volume":"34","author":"A Neeb","year":"2021","unstructured":"Neeb A et al (2021) Prognostic value of atm expression in prostate cancer: concordance between biopsy and radical prostatectomy specimens. Mod Pathol 34(7):1256\u20131265. https:\/\/doi.org\/10.1038\/s41379-021-00752-7","journal-title":"Mod Pathol"},{"issue":"5","key":"4806_CR52","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/his.14574","volume":"80","author":"E Hollemans","year":"2022","unstructured":"Hollemans E et al (2022) Diagnostic accuracy of prostate biopsy for cribriform and intraductal carcinoma: correlation with matched prostatectomy specimens. Histopathology 80(5):808\u2013817. https:\/\/doi.org\/10.1111\/his.14574","journal-title":"Histopathology"},{"issue":"4","key":"4806_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrm3546","volume":"14","author":"Y Shiloh","year":"2013","unstructured":"Shiloh Y, Ziv Y (2013) The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14(4):197\u2013210. https:\/\/doi.org\/10.1038\/nrm3546","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"18","key":"4806_CR54","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373(18):1697\u20131708. https:\/\/doi.org\/10.1056\/NEJMoa1506859","journal-title":"N Engl J Med"},{"issue":"23","key":"4806_CR55","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W et al (2019) Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci 116(23):11428\u201311436. https:\/\/doi.org\/10.1073\/pnas.1902651116","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"4806_CR56","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/PAS.0000000000001186","volume":"43","author":"M Fraser","year":"2019","unstructured":"Fraser M et al (2019) Genomic hallmarks of localized, high-risk, cribriform prostate cancer. Am J Surg Pathol 43(3):313\u2013322. https:\/\/doi.org\/10.1097\/PAS.0000000000001186","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"4806_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-33780-1","volume":"13","author":"HY Wong","year":"2022","unstructured":"Wong HY et al (2022) Single-cell analysis of cribriform prostate cancer reveals cell-intrinsic and tumor microenvironmental pathways of aggressive disease. Nat Commun 13(1):1\u201315. https:\/\/doi.org\/10.1038\/s41467-022-33780-1","journal-title":"Nat Commun"},{"issue":"1","key":"4806_CR58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/his.13029","volume":"70","author":"TL Lotan","year":"2017","unstructured":"Lotan TL, Epstein JI (2017) Morphologic patterns and molecular features of prostate cancer. Histopathology 70(1):5\u201327. https:\/\/doi.org\/10.1111\/his.13029","journal-title":"Histopathology"},{"issue":"11","key":"4806_CR59","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41585-019-0215-2","volume":"16","author":"DM Berman","year":"2019","unstructured":"Berman DM et al (2019) Molecular markers in prostate cancer: transforming the clinical landscape. Nat Rev Urol 16(11):632\u2013650. https:\/\/doi.org\/10.1038\/s41585-019-0215-2","journal-title":"Nat Rev Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04806-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04806-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:37:44Z","timestamp":1773844664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04806-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4806"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04806-6","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}